Patents by Inventor John Gerald McCafferty
John Gerald McCafferty has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 7151169Abstract: The invention provides specific binding members, for example in the form of antibody variable domains, based on the CDR3 sequences of the antibody VH regions of SL15 (SEQ ID NO:4) and JT182 (SEQ ID NO:10). The antibodies have strong neutralising activity for TGF?1 and are useful in treating conditions associated with excess TGF?1 activity, such as fibrosis, immune responses and tumor progression.Type: GrantFiled: September 13, 2002Date of Patent: December 19, 2006Assignee: Cambridge Antibody Technology LimitedInventors: Julia Elizabeth Thompson, Simon Nicholas Lennard, Alison Jane Wilton, Peta Sally Helena Braddock, Sarah Leila Du Fou, John Gerald McCafferty, Louise Anne Conroy, Philip Ronald Tempest
-
Publication number: 20030091566Abstract: The invention provides specific binding members, for example in the form of antibody variable domains, based on the CDR3 sequences of the antibody VH regions of SL15 (SEQ ID NO:4) and JT182 (SEQ ID NO:10).Type: ApplicationFiled: September 13, 2002Publication date: May 15, 2003Inventors: Julia Elizabeth Thompson, Simon Nicholas Lennard, Alison Jane Wilton, Peta Sally Helena Braddock, Sarah Leila Du Fou, John Gerald McCafferty, Louise Anne Conroy, Philip Ronald Tempest
-
Publication number: 20030064069Abstract: The invention provides specific binding members, for example in the form of antibody variable domains, based on the CDR3 sequences of the antibody VH regions of SL15 (SEQ ID NO:4) and JT182 (SEQ ID NO:10).Type: ApplicationFiled: September 13, 2002Publication date: April 3, 2003Inventors: Julia Elizabeth Thompson, Simon Nicholas Lennard, Alison Jane Wilton, Peta Sally Helena Braddock, Sarah Leila Du Fou, John Gerald McCafferty, Louise Anne Conroy, Philip Ronald Tempest
-
Patent number: 6492497Abstract: The invention provides specific binding members, for example in the form of antibody variable domains, based on the CDR3 sequences of the antibody VH regions of SL15 (SEQ ID NO:4) and JT182 (SEQ ID NO:10). The antibodies have strong neutralizing activity for TGF&bgr;1 and are useful in treating conditions associated with excess TGF&bgr;1 activity, such as fibrosis, immune responses and tumor progression.Type: GrantFiled: April 28, 2000Date of Patent: December 10, 2002Assignee: Cambridge Antibody Technology LimitedInventors: Julia Elizabeth Thompson, Simon Nicholas Lennard, Alison Jane Wilton, Peta Sally Helena Braddock, Sarah Leila Du Fou, John Gerald McCafferty, Louise Anne Conroy, Philip Ronald Tempest
-
Patent number: 6489123Abstract: A method of labelling molecules which includes providing in a common medium a label molecule, a marker ligand able to bind a member of a specific binding pair, such as an antigen, a sbp member, an enzyme able to catalyze binding of the label molecule to other molecules, the enzyme being associated with the marker ligand; causing or allowing binding of the marker ligand to the sbp member; and causing or allowing binding of the label molecule to other molecules in the vicinity of the marker ligand bound to the sbp member. The marker ligand may be an antibody or any specific binding molecule, such as a chemokine or cytokine. A complementary member of the specific binding pair may be included, e.g. an antibody, or a diverse population of such sbp members, e.g. antibodies, may be included within which those which bind the counterpart sbp member, e.g. antigen, may be labelled and subsequently isolated for manipulation and/or use.Type: GrantFiled: January 23, 2001Date of Patent: December 3, 2002Assignee: Cambridge Antibody Technology LimitedInventors: Jane Katharine Osbourn, Elaine Joy Derbyshire, John Gerald McCafferty, Tristan John Vaughan, Kevin Stuart Johnson
-
Patent number: 6342588Abstract: A method of labelling molecules which includes providing in a common medium a label molecule, a marker ligand able to bind a member of a specific binding pair, such as an antigen, a sbp member, an enzyme able to catalyse binding of the label molecule to other molecules, the enzyme being associated with the marker ligand; causing or allowing binding of the marker ligand to the sbp member; and causing or allowing binding of the label molecule to other molecules in the vicinity of the marker ligand bound to the sbp member. The marker ligand may be an antibody or any specific binding molecule, such as a chemokine or cytokine. A complementary member of the specific binding pair may be included, e.g. an antibody, or a diverse population of such sbp members, e.g. antibodies, may be included within which those which bind the counterpart sbp member, e.g. antigen, may be labelled and subsequently isolated for manipulation and/or use.Type: GrantFiled: August 16, 1999Date of Patent: January 29, 2002Assignee: Cambridge Antibody Technology LimitedInventors: Jane Katharine Osbourn, Elaine Joy Derbyshire, John Gerald McCafferty, Tristan John Vaughan, Kevin Stuart Johnson
-
Publication number: 20020004215Abstract: A method of labelling molecules which includes providing in a common medium a label molecule, a marker ligand able to bind a member of a specific binding pair, such as an antigen, a sbp member, an enzyme able to catalyze binding of the label molecule to other molecules, the enzyme being associated with the marker ligand; causing or allowing binding of the marker ligand to the sbp member; and causing or allowing binding of the label molecule to other molecules in the vicinity of the marker ligand bound to the sbp member. The marker ligand may be an antibody or any specific binding molecule, such as a chemokine or cytokine. A complementary member of the specific binding pair may be included, e.g. an antibody, or a diverse population of such sbp members, e.g. antibodies, may be included within which those which bind the counterpart sbp member, e.g. antigen, may be labelled and subsequently isolated for manipulation and/or use.Type: ApplicationFiled: January 23, 2001Publication date: January 10, 2002Applicant: Cambridge Antibody Technology, Ltd.Inventors: Jane Katharine Osbourn, Elaine Joy Derbyshire, John Gerald McCafferty, Tristan John Vaughan, Kevin Stuart Johnson
-
Patent number: 6180336Abstract: A method of labelling molecules which includes providing in a common medium a label molecule, a marker ligand able to bind a member of a specific binding pair, such as an antigen, a sbp member, an enzyme able to catalyse binding of the label molecule to other molecules, the enzyme being associated with the marker ligand; causing or allowing binding of the marker ligand to the sbp member; and causing or allowing binding of the label molecule to other molecules in the vicinity of the marker ligand bound to the sbp member. The marker ligand may be an antibody or any specific binding molecule, such as a chemokine or cytokine. A complementary member of the specific binding pair may be included, e.g. an antibody, or a diverse population of such sbp members, e.g. antibodies, may be included within which those which bind the counterpart sbp member, e.g. antigen, may be labelled and subsequently isolated for manipulation and/or use.Type: GrantFiled: June 17, 1998Date of Patent: January 30, 2001Assignee: Cambridge Antibody Technology LimitedInventors: Jane Katharine Osbourn, Elaine Joy Derbyshire, John Gerald McCafferty, Tristan John Vaughan, Kevin Stuart Johnson
-
Patent number: 5994519Abstract: A method of labelling molecules which includes providing in a common medium a label molecule, a marker ligand able to bind a member of a specific binding pair, such as an antigen, a sbp member, an enzyme able to catalyse binding of the label molecule to other molecules, the enzyme being associated with the marker ligand; causing or allowing binding of the marker ligand to the sbp member; and causing or allowing binding of the label molecule to other molecules in the vicinity of the marker ligand bound to the sbp member. The marker ligand may be an antibody or any specific binding molecule, such as a chemokine or cytokine. A complementary member of the specific binding pair may be included, e.g. an antibody, or a diverse population of such sbp members, e.g. antibodies, may be included within which those which bind the counterpart sbp member, e.g. antigen, may be labelled and subsequently isolated for manipulation and/or use.Type: GrantFiled: July 8, 1997Date of Patent: November 30, 1999Assignee: Cambridge Antibody Technology LimitedInventors: Jane Katharine Osbourn, Elaine Joy Derbyshire, John Gerald McCafferty, Tristan John Vaughan, Kevin Stuart Johnson
-
Patent number: 5872215Abstract: Specific binding members for human carcinoembryonic antigen (CEA) comprise a human antibody antigen binding domain. The specific binding members may have a dissociation constant less than 1.0.times.10.sup.-8 M and may be substantially non-crossreactive with human liver and/or other normal tissues. They may be specific for the A3-B3 extracellular domain of CEA. They may be specific for a carbohydrate epitope of CEA. They may be produced by recombinant expression from encoding nucleic acid and modified and manipulated in various manners in accordance with known techniques. CEA is a tumour antigen and the specific binding members have proven ability to bind and target CEA both in vitro and in vivo.Type: GrantFiled: May 23, 1996Date of Patent: February 16, 1999Assignees: Medical Research Council, Cambridge Antibody Technology Ltd.Inventors: Jane Katharine Osbourne, Deborah Julie Allen, John Gerald McCafferty